A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Antibody-drug conjugates hitting this target abound.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
An MSKCC study continues to show a 100% response rate in pre-operative rectal cancer.
